Goldman Sachs Group Inc. increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 51.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,456,457 shares of the biopharmaceutical company's stock after purchasing an additional 9,041,990 shares during the quarter. Goldman Sachs Group Inc. owned 0.47% of Pfizer worth $670,407,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. bought a new position in shares of Pfizer in the 1st quarter worth approximately $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the 1st quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $30,000. 68.36% of the stock is owned by institutional investors.
Pfizer Stock Performance
Shares of PFE stock traded up $0.32 on Thursday, reaching $24.25. The stock had a trading volume of 45,468,611 shares, compared to its average volume of 46,190,364. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The stock has a market cap of $137.84 billion, a P/E ratio of 12.90, a price-to-earnings-growth ratio of 0.87 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.96 and a current ratio of 1.16. The company has a 50 day simple moving average of $24.42 and a 200 day simple moving average of $24.52.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.
Wall Street Analyst Weigh In
PFE has been the subject of several recent research reports. HSBC lowered their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. The Goldman Sachs Group boosted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday. Finally, Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $28.44.
Check Out Our Latest Report on PFE
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
